Peter Antony Barbuti is currently an Associate Research Scientist at Columbia University Irving Medical Center (CUIMC), New York, USA. He is also an Adjunct Professor at Fordham University, New York, and a member of the New York Academy of Sciences. He received his BSc (Hons) in Biomedical Materials Science from the Department of Mechanical, Manufacturing, and Materials Engineering, University of Nottingham, UK, in 2007; his MSc (with Merit) in Stem Cell Technology from the School of Medicine, University of Nottingham, in 2008; and his Ph.D. from the School of Clinical Sciences, University of Bristol, UK, in 2014. Before joining Columbia University, he was a Post-Doctoral Research Associate in the Clinical and Experimental Neuroscience group at the Luxembourg Centre for Systems Biomedicine (LCSB) (2014–2019). He is currently funded by an Early Career Investigator Innovation Award from the William N. and Bernice E. Bumpus Foundation. Central to his research is the role of the alpha-synuclein (αSyn) protein in the pathogenesis of Parkinson’s disease (PD). Dr. Barbuti is currently investigating the implications of αSyn at the mitochondrial-associated ER membranes (MAMs) and how the interplay of αSyn, lipid dyshomeostasis, and neuroinflammation may contribute to PD.